G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design Market Report 2026

The g protein-coupled receptors (gpcr) structure-based drug design market size has grown rapidly in recent years. It will grow from $2.64 billion in 2025 to $3 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to advancements in gpcr crystallography techniques, increased pharmaceutical r&d spending, availability of high-resolution receptor structures, growing understanding of gpcr signaling pathways, expansion of small molecule drug discovery platforms.

The g protein-coupled receptors (gpcr) structure-based drug design market size is expected to see rapid growth in the next few years. It will grow to $4.89 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to rising adoption of ai-assisted molecular design, increasing focus on precision medicine drug development, expansion of gpcr targets in oncology and neurology, growing investments in next-generation structural biology tools, rising demand for highly selective therapeutics. Major trends in the forecast period include increasing use of structure-guided ligand optimization, rising adoption of cryo-electron microscopy for gpcr analysis, growing integration of computational modeling in drug discovery, expansion of allosteric modulator development, enhanced focus on receptor selectivity improvement.

The rising demand for precision medicine is expected to drive the growth of the G protein-coupled receptors (GPCR) structure-based drug design market in the coming years. Precision medicine refers to treatment approaches that utilize specific biological markers to guide the selection and development of therapies tailored to the unique characteristics and disease profiles of individual patients. The growing demand for precision medicine is fueled by their higher efficacy and lower side effects compared to conventional treatments, as healthcare systems increasingly focus on personalized strategies that target specific molecular pathways rather than broad-spectrum interventions. This increasing focus on precision medicine directly boosts the adoption of GPCR structure-based drug design platforms, as pharmaceutical companies require advanced computational tools to identify and optimize receptor-specific compounds capable of delivering the molecular precision needed for personalized therapies. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a notable increase from six approvals in 2022. Among these newly approved therapies, seven are cancer drugs, while three address other diseases and conditions. Thus, the growing demand for precision medicine is driving the expansion of the G protein-coupled receptors (GPCR) structure-based drug design market.

Major companies operating in the G-protein coupled receptor (GPCR) structure-based drug design market are concentrating on developing innovative solutions such as structure-based drug design platforms to accelerate the discovery of novel drugs and enhance therapeutic targeting. Structure-based drug design platforms are computational and experimental tools that leverage the three-dimensional (3D) structure of target proteins to design and optimize drug candidates, facilitating the identification of more precise, effective, and safer therapies. For example, in January 2025, Septerna Inc., a US-based pharmaceutical company, initiated new efforts to advance its Native Complex Platform, following the $100 million Series A financing it had raised. The platform enables structure-based drug design for GPCRs by preserving their native structure and dynamics outside of the cellular environment, supporting the creation of a pipeline of GPCR-targeted therapies aimed at previously undruggable targets across multiple therapeutic areas, while also providing a scalable foundation for industrialized drug discovery, integration of novel screening technologies, and identification of new mechanisms of GPCR modulation. The platform further offers opportunities to systematically investigate the entire GPCR superfamily, paving the way for a broader range of therapeutic interventions.

In May 2024, Incyte Corporation, a US-based biopharmaceutical company, acquired Escient Pharmaceuticals, Inc. for $750 million. Through this acquisition, Incyte intends to enhance its Inflammation and Autoimmunity pipeline by incorporating first-in-class oral GPCR-targeting MRGPR antagonists, EP262 and EP547, which inhibit key Mas-related G protein-coupled receptors involved in mast cell activation and severe pruritus, thereby promoting the development of innovative therapies for a wide range of mast cell-mediated and cholestatic pruritus-related conditions with significant unmet medical need. Escient Pharmaceuticals Inc. is a US-based biopharmaceutical company focused on developing first-in-class oral antagonists targeting mas-related G protein-coupled receptor X2 (MRGPRX2) and mas-related G protein-coupled receptor X4 (MRGPRX4).

Major companies operating in the g protein-coupled receptors (gpcr) structure-based drug design market are F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi S.A., AstraZeneca plc, Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., Evotec SE, Acadia Pharmaceuticals Inc., Promega Corporation, Domain Therapeutics SA, Schrödinger Inc., Kallyope Inc., Domainex Ltd., Structure Therapeutics Inc., Creative Biolabs Inc., InterAx Biotech Inc., Abalone Bio Inc., Octant Inc.

North America was the largest region in the G protein-coupled receptors (GPCR) structure-based drug design market in 2025. The regions covered in the g protein-coupled receptors (gpcr) structure-based drug design market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the g protein-coupled receptors (gpcr) structure-based drug design market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gpcr structure-based drug design market by increasing costs of imported cryo-electron microscopy equipment, x-ray crystallography instruments, high-performance computing hardware, and specialized laboratory consumables. Research institutions and pharmaceutical companies in North America and Europe are most affected due to reliance on imported advanced imaging and computational infrastructure, while Asia-Pacific faces higher costs for technology imports. These tariffs are increasing capital expenditure and extending research timelines for drug discovery programs. However, they are also encouraging localized manufacturing of research equipment, regional collaborations, and increased investment in domestic structural biology capabilities.

The g protein-coupled receptors (gpcr) structure-based drug design market research report is one of a series of new reports that provides g protein-coupled receptors (gpcr) structure-based drug design market statistics, including g protein-coupled receptors (gpcr) structure-based drug design industry global market size, regional shares, competitors with a g protein-coupled receptors (gpcr) structure-based drug design market share, detailed g protein-coupled receptors (gpcr) structure-based drug design market segments, market trends and opportunities, and any further data you may need to thrive in the g protein-coupled receptors (gpcr) structure-based drug design industry. This g protein-coupled receptors (gpcr) structure-based drug design market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

G protein-coupled receptors (GPCR) structure-based drug design is an approach that involves developing drugs by utilizing the detailed three-dimensional structures of GPCRs to enhance the binding and selectivity of new compounds. This strategy allows researchers to create molecules that interact precisely with the atomic-level characteristics of GPCR binding sites, increasing specificity and reducing off-target effects.

The primary drug types in G protein-coupled receptor (GPCR) structure-based drug design include small molecules, biologics, peptides, and other drug categories. Small-molecule drugs are low-molecular-weight compounds that can readily enter cells to selectively modulate biological targets, such as enzymes or receptors. A variety of technologies are employed in drug development, including X-ray crystallography, cryo-electron microscopy, computational modeling, and nuclear magnetic resonance (NMR) spectroscopy. These methods are applied across multiple therapeutic areas, such as oncology, cardiovascular diseases, neurological disorders, and metabolic disorders, and are used by end-users including pharmaceutical companies, biotechnology firms, academic institutions, and research organizations.

The G protein-coupled receptors (GPCR) structure-based drug design market consists of revenues earned by entities by providing services such as computational modeling, assay development and screening, hit identification and lead optimization, medicinal chemistry and compound synthesis, biologics and antibody development, specialized assay services for safety, efficacy, and biomarker discovery. The market value includes the value of related goods sold by the service provider or included within the service offering. The G protein-coupled receptors (GPCR) structure-based drug design market also includes sales of GPCR-expressing cell lines, detection kits, cell culture reagents, ligands, and assay systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.